Drugs / HEC96719
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04546984 | Sep → Dec 2020 | metabolic dysfunction-associated steatohepatitis | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04422496 | Aug 2020 → Feb 2021 | NAFLD1, metabolic dysfunction-associated steatohepatitis | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04194242 | Jan → Jul 2020 | metabolic dysfunction-associated steatohepatitis | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05397379 | Nov 2021 → Sep 2023 | metabolic dysfunction-associated steatohepatitis | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HEC96719 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04422496 ↗ |
| Route | Oral | “escalating single oral doses of HEC96719” NCT04194242 ↗ |